S. Panigoro (Jakarta, Indonesia)

Faculty of Medicine, Universitas Indonesia

Author Of 1 Presentation

 On-Demand ePoster Display

135P - Relationship between low muscle mass pre-chemotherapy with hematological toxicity in breast cancer patients after 3 cycles of chemotherapy

Abstract

Background

Breast cancer patients undergoing chemotherapy often reported side effects, including fatigue, nausea, vomiting, and unintentional weight loss. Change in body composition, especially decreased muscle mass is known to have important impact of anticancer drug toxicity. Currently, there is still limited data regarding this issue. The aim of the study was to know the relationship between low muscle mass (LMM) and chemotherapy toxicity in breast cancer patients.

Methods

A prospective cohort study of adult women breast cancer was conducted in second cancer referral hospital at Banten, Indonesia. Naïve breast cancer patients were evaluated for LMM using Bio-impedance electrical analysis (BIA) before they underwent chemotherapy. LMM cut off was using Asian working group of sarcopenia criteria <5.7kg/m2. They were followed up for hematological side effects according to common terminology criteria for adverse events (CTCAE) v4.0. Several confounding factors were also evaluated. Chi-square was used to evaluate the relationships between them and continue to logistic regression analysis if the results were significant.

Results

Sixty eight of 128 subjects completed to be evaluated until the end of 3 cycles of chemotherapy. The median of age was 47(25-59) year old. More than half were overweight and obese. Fifty six percent subject were in early stage. The subjects were using either Taxane or Anthracycline based chemotherapy regimen. The menopausal status almost equal. Thirty five percent subject were needed social support. LMM was found in 15(22%) subject. The toxicities mostly anemia and thrombocytopenia were found in 16(23.5%) subject. LMM was associated with toxicities OR(CI) 2.170(1.157-4.068) p<0.000. Early stage was associated with toxicities OR(CI) 1.272 (1.210-2.465) p < 0.000. Body mass index, C-reactive protein, chemotherapy regimen, comorbidity, and performance status were not associated with toxicities. After adjusted with stage and body mass index, LMM still associated with toxicities OR(CI) 6.181(1.494-25.585) p 0.012.

Conclusions

Low muscle mass before chemotherapy was associated with hematological toxicity in breast cancer patients after 3 cycles of chemotherapy.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Collapse